Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Lymphocytic Herpesviruses and Cerebrospinal Fluid Polymerase Chain Reaction (PCR)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2011 by PaijatHame Central Hospital.
Recruitment status was  Not yet recruiting
Sponsor:
Collaborator:
University of Turku
Information provided by (Responsible Party):
Laura Kupila, PaijatHame Central Hospital
ClinicalTrials.gov Identifier:
NCT01438879
First received: September 20, 2011
Last updated: September 21, 2011
Last verified: September 2011

September 20, 2011
September 21, 2011
October 2011
October 2013   (final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT01438879 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Lymphocytic Herpesviruses and Cerebrospinal Fluid Polymerase Chain Reaction (PCR)
Molecular Methods in the Etiological Diagnostics of Acute Central Nervous System Infections: Lymphocytic Herpesviruses and PCR

Enterovirus and herpes simplex viruses 1 and 2 are the main causative agents of central nervous system infections.

Instead, the role of lymphocytic herpesviruses in the etiology of central nervous system (CNS) infections is not clear, even if there is the positive cerebrospinal fluid (CSF) polymerase chain reaction (PCR)-result for the virus.

The aim of this study is to evaluate the presence of DNA from lymphocytic herpesviruses in the CSF obtained from the immunocompetent patients with CSF pleocytosis and from the patients with normal CSF leukocyte count.

Not Provided
Observational
Observational Model: Case Control
Time Perspective: Prospective
Not Provided
Retention:   Samples With DNA
Description:

CSF white cells + CSF supernatant, Blood white cells and serum

Non-Probability Sample

Residents of the district of Paijat-Hame (200 000 inhabitants).

Central Nervous System Infection
Not Provided
  • pleocytosis group
    40 patients with clinical signs of CNS infection and having CSF pleocytosis.
  • non-pleocytosis group
    20 patients not having CNS infection clinically and not having CSF pleocytosis.
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Not yet recruiting
60
December 2013
October 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Immunocompetent patients with clinical symptoms and signs of central nervous system infections and CSF pleocytosis (pleocytosis group)
  • Immunocompetent patients without suspicion of CNS infection and no CSF pleocytosis (non-pleocytosis group)

Exclusion Criteria:

  • Suspicion of CNS-infection, eg. encephalitis, but no CSF leukocytosis (pleocytosis group)
  • Patients without symptoms of CNS infection, but who has CSF pleocytosis of unknown origin (non-pleocytosis group)
Both
16 Years to 80 Years
No
Contact: Laura MA Kupila +358447195940 laura.kupila@phsotey.fi
Finland
 
NCT01438879
R11077
No
Laura Kupila, PaijatHame Central Hospital
PaijatHame Central Hospital
University of Turku
Principal Investigator: Laura MA Kupila PaijatHame Central Hospital
PaijatHame Central Hospital
September 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP